Risks

Current ratio and quick ratio are far below peers, so near-term liquidity stress can constrain operating flexibility and financing access versus better-capitalized medtech peers.

Interest coverage is deeply negative, meaning ongoing losses can force dilutive funding or restructuring sooner than profitable peers with self-funding balance sheets.

Days payable outstanding is extremely elevated, which can signal supplier strain and tighter trade terms versus peers with more normal working-capital cycles.

Negative net debt to EBITDA reflects the absence of meaningful EBITDA support, so leverage metrics remain less resilient than peers with positive earnings power.

Opportunities

The negative cash conversion cycle suggests working-capital release potential, which could improve liquidity faster than peers if collections and inventory discipline normalize.

Low reported debt-to-equity can support optionality for financing or restructuring versus more levered peers, provided lenders remain willing to extend terms.

If operating scale improves, the current low fixed-charge burden could allow margin recovery to outpace peers that already carry heavier debt service.

Overall Score

VTAK’s forward positioning is dominated by severe liquidity and coverage risk, while limited upside from working-capital improvement and financing optionality remains secondary versus peers.